Clinical Trials Logo

Degenerative Disc Disease clinical trials

View clinical trials related to Degenerative Disc Disease.

Filter by:

NCT ID: NCT01018771 Completed - Clinical trials for Degenerative Disc Disease

Actifuse ABX Versus INFUSE in Posterolateral Instrumented Lumbar Fusion

APPRAISET2
Start date: July 2009
Phase: N/A
Study type: Interventional

This is a prospective randomised study. Primary objective: Evaluation of success rates of Actifuse ABX and INFUSE in achieving bone fusion. Secondary objectives: Assess clinical outcome measurements.

NCT ID: NCT01013389 Completed - Clinical trials for Degenerative Disc Disease

Actifuse ABX Versus INFUSE in Posterolateral Instrumented Lumbar Fusion (PLIF) With Interbody Fusion

APPRAISET1
Start date: June 2007
Phase: N/A
Study type: Interventional

The primary objective of this clinical trial is to evaluate the success rates of Actifuse ABX and INFUSE in achieving bone fusion. The secondary objective of this clinical trial is to assess clinical outcome measurements.

NCT ID: NCT00996073 Completed - Clinical trials for Degenerative Disc Disease

Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody Fusion

Start date: September 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and preliminary efficacy of NeoFuse in subjects with a diagnosis of degenerative disc disease (DDD) in 1 or 2 adjacent vertebral levels between L1 and S1. All subjects in this study will undergo interbody fusion via Transforaminal Lumbar Interbody Fusion (TLIF) or Posterior Lumbar Interbody Fusion (PLIF) procedures with Food and Drug Administration (FDA) approved/cleared supplemental posterior instrumentation.

NCT ID: NCT00965380 Completed - Clinical trials for Degenerative Disc Disease

Trinity Evolution in Posterior or Transforaminal Lumbar Interbody Fusion (PLIF/TLIF)

TLF
Start date: September 2009
Phase:
Study type: Observational

The purpose of this study is to utilize Trinity Evolution in conjunction with an interbody spacer and supplemental posterior fixation of the surgeon's choice and to follow the patients to measure the clinical outcomes and rate of fusion. The hypothesis of the study is that Trinity Evolution combined with an interbody spacer and supplemental posterior fixation will result in fusion rates and clinical outcomes similar to those with other routinely used autograft and allograft materials including: fusion, improvement in pain and function, maintenance of lower extremity neurological function, and absence of serious adverse events related to the use of the Trinity Evolution product.

NCT ID: NCT00951938 Completed - Clinical trials for Degenerative Disc Disease

Trinity Evolution in Anterior Cervical Disectomy and Fusion (ACDF)

Start date: August 2009
Phase: N/A
Study type: Observational

The purpose of this study is to utilize Trinity Evolution in conjunction with an interbody spacer and supplemental anterior fixation of the surgeon's choice and to follow the patients to measure the clinical outcomes and rate of fusion. The hypothesis of the study is that Trinity Evolution combined with an interbody spacer and supplemental anterior fixation will result in fusion rates and clinical outcomes similar to those with other routinely used autograft and allograft materials including: fusion, improvement in pain and function, maintenance of upper extremity neurological function, and absence of serious adverse events related to the use of the Trinity Evolution product.

NCT ID: NCT00948532 Completed - Back Pain Clinical Trials

Osteocel® Plus in eXtreme Lateral Interbody Fusion (XLIF®)

Start date: March 2009
Phase: N/A
Study type: Observational

This is a prospective, non-randomized multi-center study to compare the use of Osteocel® Plus in subjects who receive XLIF® (eXtreme Lateral Interbody Fusion) surgery at one or two levels. These subjects will present with degenerative conditions in the lumbar spine that are amenable to surgical treatment and will be screened prior to study enrollment. Subjects will receive Osteocel Plus during their XLIF operation. Subjects will be followed for 24-months following surgery to determine the number of study subjects that are solidly fused at or before 24 months postoperatively, and to determine the mean time to fusion. This data will be compared to published and/or retrospective data for autograft, synthetic ceramics and Bone Morphogenetic Protein (BMP).

NCT ID: NCT00947583 Completed - Clinical trials for Degenerative Disc Disease

Osteocel® Plus in Transforaminal Lumbar Interbody Fusion (TLIF)

Start date: May 2009
Phase: N/A
Study type: Observational

This study is being conducted to determine the percentage of patients with solid spinal fusions after being treated with Osteocel Plus in a TLIF procedure. Due to the unique processing conditions, Osteocel Plus retains a high concentration of stem cells in conjunction with the allograft bone matrix, so it is hypothesized that the fusion rate with Osteocel Plus will be comparable to published data for autograft. The Osteocel product family has already been used in approximately 15,000 cases worldwide.

NCT ID: NCT00941980 Completed - Clinical trials for Degenerative Disc Disease

Osteocel® Plus in Posterior Lumbar Interbody Fusion (PLIF)

Start date: June 2009
Phase: N/A
Study type: Observational

This study is being conducted to determine the percentage of patients with solid spinal fusions after being treated with Osteocel Plus in a PLIF procedure. Due to the unique processing conditions, Osteocel Plus retains a high concentration of stem cells attached to the allograft bone matrix, so it is hypothesized that the fusion rate with Osteocel Plus will be comparable to published data for autograft. The Osteocel product family has already been used in approximately 20,000 cases worldwide.

NCT ID: NCT00931515 Completed - Clinical trials for Degenerative Disc Disease

Trial Evaluating the Safety and Effectiveness of NUBACâ„¢ Disc Arthroplasty

Start date: February 2009
Phase: N/A
Study type: Interventional

The NuBac device is indicated for reconstruction following nucleotomy in skeletally mature patients at least 18 years of age with symptomatic single level degenerative disc disease (DDD) at L4/L5 only. DDD is defined as discogenic back pain with or without leg pain; with degeneration of the disc as confirmed by patient history, physical examination, radiographic studies showing: decreased disc height, contained herniated nucleus, vacuum phenomenon (dark disc) OR positive discography at the affected level. These DDD patients should have no more than Grade 1 spondylolisthesis at the involved level and should have failed at least six months of conservative, non-operative care. Demonstrate non-inferiority compared to ProDisc.

NCT ID: NCT00927238 Completed - Clinical trials for Degenerative Disc Disease

XL TDR® eXtreme Lateral Total Disc Replacement for the Treatment of Lumbar Degenerative Disc Disease (DDD)

XL TDR
Start date: July 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of XL TDR in patients with single-level degenerative disc disease compared to other devices approved by the FDA for the same or similar indications.